Allakos recently presented preclinical data demonstrating the potential of its Siglec-8 antibodies in inhibiting components involved in fibrosis in rodent models of lung and skin fibrosis. The company believes these antibodies could potentially benefit a wide spectrum of patients with conditions where fibrosis is a major contributor to the…
Preclinical Data Support Start of Clinical Studies of Potential Treatment for IPF and Other Fibrotic Diseases
What is Aromatherapy? Have you heard about essential oils? They aren’t anything new. “Essential oil” is basically a different name for an old standby, aromatherapy. There’s plenty of research behind this aromatic trend that shows it can help to alleviate many health conditions. We’ve uncovered some ways essential oils can help you deal…
In this PeerView Press video, pulmonologist Dr. David J. Lederer discusses idiopathic pulmonary fibrosis (IPF), with a focus on personalized care through communications and innovative strategies. He is joined by primary care physician Dr. Steven J. Antonini and pulmonary fibrosis patient Robert Brynteson. Read about six lesser-known symptoms…
Building on previous research, scientists at Brown University report that a trio of proteins work together to promote a variety of lung diseases, including idiopathic pulmonary fibrosis (IPF). The findings, published by investigators led by Jack Elias in the journal Nature Communications, appeared in the article “IL-13Rα2 Uses TMEM219 In…
Pulmonary fibrosis is a chronic severe lung disease that occurs when lung tissue becomes scarred and thickened. Patients struggle with breathing difficulties, a persistent dry cough, fatigue, weight loss, and clubbing of the fingers. Read about six less common symptoms of idiopathic pulmonary fibrosis here. In this video from Boehringer Ingelheim Idiopathic…
Global Blood Therapeutics (GBT) recently published positive preclinical results supporting the development of GBT440 for the treatment of lung diseases associated with hypoxemia (abnormally low levels of oxygen in the blood), such as idiopathic pulmonary fibrosis (IPF). The results were detailed in the study, “Increased hemoglobin–oxygen affinity ameliorates bleomycin‐induced hypoxemia…
Idiopathic pulmonary fibrosis is a relatively rare and serious condition. Although men tend to be affected more than women, anyone can get the disease. Some risk factors for IPF are smoking, working with environmental pollutants, acid reflux, and a family history of the disease. Read our article Simple Facts…
According to the Mayo Clinic, though no current cure for pulmonary fibrosis exists yet, medications and other treatment options can help improve a patient’s quality of life. As the disease evolves, several complications may arise. Here is a list of six possible pulmonary fibrosis complications: 1. High blood pressure in the lungs: Unlike normal high…
Researchers used stem cells from patients with idiopathic pulmonary fibrosis (IPF) to create a lung “organoid” — a three-dimensional structure similar to the human lung — that stands to improve studies into lung diseases like IPF and research into personalized drug therapies, by allowing such investigations to take place in an environment…
It’s been proven that pulmonary rehabilitation helps patients with pulmonary diseases such as chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and pulmonary hypertension among others. Just because you have pulmonary fibrosis doesn’t mean you can’t travel by airplane. Learn more here. Providence…
